|
1
|
Molinaro E, Romei C, Biagini A, Sabini E,
Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini
A, Torregrossa L, et al: Anaplastic thyroid carcinoma: From
clinicopathology to genetics and advanced therapies. Nat Rev
Endocrinol. 13:644–660. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smallridge RC and Copland JA: Anaplastic
thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol
(R Coll Radiol). 22:pp. 486–497. 2010, View Article : Google Scholar
|
|
3
|
Quinn JJ and Chang HY: Unique features of
long non-coding RNA biogenesis and function. Nat Rev Genet.
17:47–62. 2016. View Article : Google Scholar
|
|
4
|
Murugan AK, Munirajan AK and Alzahrani AS:
Long noncoding RNAs: Emerging players in thyroid cancer
pathogenesis. Endocr Relat Cancer. 25:R59–R82. 2018. View Article : Google Scholar
|
|
5
|
Chakravarty D, Sboner A, Nair SS,
Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K,
Kossai M, et al: The oestrogen receptor alpha-regulated lncRNA
NEAT1 is a critical modulator of prostate cancer. Nat Commun.
5:53832014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen ZJ, Zhang Z, Xie BB and Zhang HY:
Clinical significance of up-regulated lncRNA NEAT1 in prognosis of
ovarian cancer. Eur Rev Med Pharmacol Sci. 20:3373–3377.
2016.PubMed/NCBI
|
|
7
|
Choudhry H, Albukhari A, Morotti M, Haider
S, Moralli D, Smythies J, Schödel J, Green CM, Camps C, Buffa F, et
al: Tumor hypoxia induces nuclear paraspeckle formation through
HIF-2a dependent transcriptional activation of NEAT1 leading to
cancer cell survival. Oncogene. 34:4482–4490. 2015. View Article : Google Scholar
|
|
8
|
Chen X, Kong J, Ma Z, Gao S and Feng X: Up
regulation of the long non-coding RNA NEAT1 promotes esophageal
squamous cell carcinoma cell progression and correlates with poor
prognosis. Am J Cancer Res. 5:2808–2815. 2015.PubMed/NCBI
|
|
9
|
Hu Y, Yang Q, Wang L, Wang S, Sun F, Xu D
and Jiang J: Knockdown of the oncogene lncRNA NEAT1 restores the
availability of miR-34c and improves the sensitivity to cisplatin
in osteosarcoma. Biosci Rep. 38:pp. pii: BSR201803752018,
View Article : Google Scholar
|
|
10
|
An J, Lv W and Zhang Y: LncRNA NEAT1
contributes to paclitaxel resistance of ovarian cancer cells by
regulating ZEB1 expression via miR-194. Onco Targets Ther.
10:5377–5390. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao C, Zhang J, Wang Q and Ren C:
Overexpression of lncRNA NEAT1 mitigates multidrug resistance by
inhibiting ABCG2 in leukemia. Oncol Lett. 12:1051–1057. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li JH, Zhang SQ, Qiu XG, Zhang SJ, Zheng
SH and Zhang DH: Long non-coding RNA NEAT1 promotes malignant
progression of thyroid carcinoma by regulating miRNA-214. Int J
Oncol. 50:708–716. 2017. View Article : Google Scholar
|
|
13
|
Zhang H, Cai Y, Zheng L, Zhang Z, Lin X
and Jiang N: Long noncoding RNA NEAT1 regulate papillary thyroid
cancer progression by modulating miR-1295p/KLK7 expression. J Cell
Physiol. 233:6638–6648. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hammond SM: An overview of microRNAs. Adv
Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qi X, Zhang DH, Wu N, Xiao JH, Wang X and
Ma W: ceRNA in cancer: Possible functions and clinical
implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Shaha AR: TNM classification of thyroid
carcinoma. World J Surg. 31:879–887. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barth S, Glick D and Macleod KF:
Autophagy: Assays and artifacts. J Pthol. 221:117–124. 2010.
View Article : Google Scholar
|
|
20
|
Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu
XY, Yu ZW, Jia YH, Bai XF, Li L and Cui BB: The lncRNA CRNDE
promotes colorectal cancer cell proliferation and chemoresistance
via miR-181a5p-mediated regulation of Wnt/β-catenin signaling. Mol
Cancer. 16:92017. View Article : Google Scholar
|
|
21
|
Gu P, Chen X, Xie R, Han J, Xie W, Wang B,
Dong W, Chen C, Yang M, Jiang J, et al: lncRNA HOXD-AS1 regulates
proliferation and chemo-resistance of castration-resistant prostate
cancer via recruiting WDR5. Mol Ther. 25:1959–1973. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshida K, Toden S, Ravindranathan P, Han
H and Goel A: Curcumin sensitizes pancreatic cancer cells to
gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1
expression. Carcinogenesis. 38:1036–1046. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang XM, Liu Y, Fan YX, Liu Z, Yuan QL,
Jia M, Geng ZS, Gu L and Lu XB: LncRNA PTCSC3 affects drug
resistance of anaplastic thyroid cancer through STAT3/INO 80
pathway. Cancer Biol Ther. 19:590–597. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu F, Tai Y and Ma J: LncRNA
NEAT1/let-7a5paxis regulates the cisplatin resistance in
nasopharyngeal carcinoma by targeting Rsf-1 and modulating the
Ras-MAPK pathway. Cancer Biol Ther. 19:534–542. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang J, Zhao B, Chen X, Wang Z, Xu H and
Huang B: Silence of long noncoding RNA NEAT1 inhibits malignant
biological behaviors and chemotherapy resistance in gastric cancer.
Pathol Oncol Res. 24:109–113. 2018. View Article : Google Scholar
|
|
26
|
Jiang P, Wu X, Wang X, Huang W and Feng Q:
NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin
sensitivity in lung cancer cells. Oncotarget. 7:43337–43351.
2016.PubMed/NCBI
|
|
27
|
Adriaens C, Standaert L, Barra J, Latil M,
Verfaillie A, Kalev P, Boeckx B, Wijnhoven PW, Radaelli E, Vermi W,
et al: p53 induces formation of NEAT1 lncRNA-containing
paraspeckles that modulate replication stress response and
chemosensitivity. Nat Med. 22:861–868. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Parasramka M, Yan IK, Wang X, Nguyen P,
Matsuda A, Maji S, Foye C, Asmann Y and Patel T: BAP1 dependent
expression of long non-coding RNA NEAT-1 contributes to sensitivity
to gemcitabine in cholangiocarcinoma. Mol Cancer. 16:222017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xie Q, Lin S, Zheng M, Cai Q and Tu Y:
Long noncoding RNA NEAT1 promoted the growth of cervical cancer
cells via sponging miR-95p. Biochem Cell Biol. 97:100–108. 2018.
View Article : Google Scholar
|
|
30
|
Lujambio A, Calin GA, Villanueva A, Ropero
S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso
MS, Faller WJ, et al: A microRNA DNA methylation signature for
human cancer metastasis. Proc Natl Acad Sci USA. 105:13556–13561.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gwak JM, Kim HJ, Kim EJ, Chung YR, Yun S,
Seo AN, Lee HJ and Park SY: MicroRNA-9 is associated with
epithelial-mesenchymal transition, breast cancer stem cell
phenotype, and tumor progression in breast cancer. Breast Cancer
Res Treat. 147:39–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park YR, Lee ST, Kim SL, Liu YC, Lee MR,
Shin JH, Seo SY, Kim SH, Kim IH, Lee SO and Kim SW: MicroRNA-9
suppresses cell migration and invasion through downregulation of
TM4SF1 in colorectal cancer. Int J Oncol. 48:2135–2143. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gomez GG, Volinia S, Croce CM, Zanca C, Li
M, Emnett R, Gutmann DH, Brennan CW, Furnari FB and Cavenee WK:
Suppression of microRNA-9 by mutant EGFR signaling upregulates
FOXP1 to enhance glioblastoma tumorigenicity. Cancer Res.
74:1429–1439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao HM, Wei W, Sun YH, Gao JH, Wang Q and
Zheng JH: MicroRNA-9 promotes tumorigenesis and mediates
sensitivity to cisplatin in primary epithelial ovarian cancer
cells. Tumour Biol. 36:6867–6873. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pan Q, Sun L, Zheng D, Li N, Shi H, Song
J, Shao G and Xu G: MicroRNA-9 enhanced cisplatin sensitivity in
nonsmall cell lung cancer cells by regulating eukaryotic
translation initiation factor 5A2. Biomed Res Int.
2018:17690402018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Munoz JL, Rodriguez-Cruz V, Ramkissoon SH,
Ligon KL, Greco SJ and Rameshwar P: Temozolomide resistance in
glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic
hedgehog level. Oncotarget. 6:1190–1201. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guo F, Hou X and Sun Q: MicroRNA-9-5p
functions as a tumor suppressor in papillary thyroid cancer via
targeting BRAF. Oncol Lett. 16:6815–6821. 2018.PubMed/NCBI
|
|
38
|
Zhang L, Yan L, Cao M, Zhang H, Li C, Bai
Y, Yu P, Li M and Zhao X: SPAG9 promotes endometrial carcinoma cell
invasion through regulation of genes related to the
epithelial-mesenchymal transition. Eur J Gynaecol Oncol.
37:312–319. 2016.PubMed/NCBI
|
|
39
|
Ren B, Wei X, Zou G, He J, Xu G, Xu F,
Huang Y, Zhu H, Li Y, Ma G and Yu P: Cancer testis antigen SPAG9 is
a promising marker for the diagnosis and treatment of lung cancer.
Oncol Rep. 35:2599–2605. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jagadish N, Gupta N, Agarwal S, Parashar
D, Sharma A, Fatima R, Topno AP, Kumar V and Suri A:
Sperm-associated antigen 9 (SPAG9) promotes the survival and tumor
growth of triple-negative breast cancer cells. Tumour Biol.
37:13101–13110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ren B, Luo S, Xu F, Zou G, Xu G, He J,
Huang Y, Zhu H and Li Y: The expression of DAMP proteins HSP70 and
cancer-testis antigen SPAG9 in peripheral blood of patients with
HCC and lung cancer. Cell Stress Chaperones. 22:237–244. 2017.
View Article : Google Scholar :
|
|
42
|
Zhen Z, Dong F, Shen H, Wang QG, Yang L
and Hu J: MiR-524 inhibits cell proliferation and induces cell
apoptosis in thyroid cancer via targeting SPAG9. Eur Rev Med
Pharmacol Sci. 22:3812–3818. 2018.PubMed/NCBI
|
|
43
|
Yang C, Shen B, Zhang J and Zhang Q:
Sperm-associated antigen 9 overexpression correlates with poor
prognosis and insensitive to Taxol treatment in breast cancer.
Biomarkers. 21:62–67. 2016. View Article : Google Scholar
|
